fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Methylphenidate HCL

All products: general benefit

Biphentin · DIN 02277131 · 15 mg · extended release capsule

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: innoviCares lists Biphentin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Biphentin · DIN 02277131 Manufacturer: Elvium Life Sciences; listing date 2009-08-18 Health Canada: Marketed since 2020-09-03 · brand BIPHENTIN · ATC N06BA04 METHYLPHENIDATE · form Capsule (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 15 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02277131)

Source record
DIN 02277131: Biphentin Raw flags: sec3=Y Item: 282000033; group id 516; item number 1385; lccId None; manufacturer id ELV Source form: ER Cap; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $1.4750; ministry $0.7354 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02277131 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76279 Therapeutic Notes (formulary) Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following: 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers. Administrative barriers include: - inability of a school to dose the child at lunch; - the school lunch hour does not coincide with the dosing schedule; - poor compliance with noon or afternoon doses; - the patient is unable to swallow tablets. Societal barriers include: - the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives; - the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
PMS-Methylphenidate CR · DIN 02536951 · $0.7354
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (N06BA): coverage varies; not interchangeable

  • Dextroamphetamine (Dexedrine Spansules): general benefit
  • Lisdexamfetamine (Vyvanse): general benefit, not a benefit
  • Mixed salt amphetamine (Adderall XR): general benefit
  • Modafinil (Alertec): not a benefit
Other drugs in the same formulary class (28:20 C.N.S. Stimulants) and how they are covered

Matched class: 28:20 C.N.S. Stimulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: DEXTROAMPHETAMINE SULFATE, MIXED SALT AMPHETAMINE Some products covered without a code (check the product listing): LISDEXAMFETAMINE DIMESYLATE 28:20 C.N.S. Stimulants

DEXTROAMPHETAMINE SULFATE

· 6 products · General benefit · strengths: 10mg, 15mg, 5mg · SR Cap, Tab

LISDEXAMFETAMINE DIMESYLATE

· 60 products · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg · Cap, Chew Tab

MIXED SALT AMPHETAMINE

· 24 products · General benefit · strengths: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg · ER Cap

MODAFINIL

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:20
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: an integral part of a total treatment program for adhd that may include other measures
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DEXTROAMPHETAMINE SULFATE, MIXED SALT AMPHETAMINE ATOMOXETINE HCL · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) Need for Comprehensive Treatment Program TEVA-ATOMOXETINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00052053.PDF; date July 2, 2019; DIN 02314541; fetched 2026-09-10 Product monograph DEXTROAMPHETAMINE SULFATE · General benefit Need for Comprehensive Treatment Program: DEXEDRINE/DEXEDRINE SPANSULE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00083629.PDF; date FEB 25, 2026; DIN 01924516; fetched 2026-09-10 Product monograph GUANFACINE · Limited Use, codes 540 Need for Comprehensive Treatment Program INTUNIV XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph LISDEXAMFETAMINE DIMESYLATE · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) Need for Comprehensive Treatment Program VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081828.PDF; date 2025-09-15; DIN 02322951; fetched 2026-09-10 Product monograph MIXED SALT AMPHETAMINE · General benefit Indications ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: • Children (6 – 12 years of age) • Adolescents (13 – 17 years of age) • Adults (18 years of age or older) Need for Comprehensive Treatment Program ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081719.PDF; date 2025-09-12; DIN 02248808; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATION AND CLINICAL USE pms-METHYLPHENIDATE is indicated for the treatment of:  Attention Deficit Hyperactivity Disorder (ADHD) Need for Comprehensive Treatment Program pms-METHYLPHENIDATE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment medication will depend upon the healthcare professional’s assessment of the chronicity and severity of the patient’s symptoms. Long-Term Use The effectiveness of Methylphenidate Hydrochloride Tablets for long-term use, i.e. for more than 4 weeks has not been systematically evaluated in placebo-controlled trials. Therefore, the healthcare profe… https://pdf.hres.ca/dpd_pm/00068339.PDF PM date: October 17, 2022 Source product: PMS-METHYLPHENIDATE; DIN 00584991; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18